A New Diagnostic Test that Can Improve the Treatment of Breast Cancer

TORONTO, Nov. 17, 2011 /CNW/ - HTX today announced it is providing $100,000 in financing to Rna Diagnostics Inc. to support the development of the RNA Disruption Assay (RDA) through their Innovation Development Program. RDA is a diagnostic test aimed to assist oncologists in determining whether or not the chemotherapy is effective early in the treatment of breast cancer.  The intellectual property for the RDA test came from the research of Dr. Amadeo Parissenti, Professor of biochemistry at Laurentian University relating to tumour resistance.

Dr. Ken Pritzker, the CEO of Rna Diagnostics Inc. and former Head of Pathology and Laboratory Medicine at Mount Sinai Hospital, states "The RDA test addresses an unmet clinical need in breast cancer management in predicting whether or not the chemotherapy will be effective early in treatment.  By identifying non-responders early in treatment, they can be spared the toxic side effects of continued treatment with ineffective chemotherapy. HTX's funding is important for the ongoing development of the RDA test in collaboration with Laurentian University and the University of Waterloo. We are grateful for their support in helping us achieve critical development milestones which are necessary for subsequent clinical development."

John Soloninka, HTX's President and CEO comments, "Ineffective chemotherapy is not only harmful to patients but also costly to healthcare systems. RDA has the potential to dramatically improve patient outcomes in breast cancer patients such that non responders can be identified quickly and drug treatment can be changed or altered. This represents a potential paradigm shift in breast cancer treatment and improves the overall management of the disease."

"The incredible work that HTX does is boosting our economy, creating jobs and improving health care," said Brad Duguid, Ontario Minister of Economic Development and Innovation.  "This partnership will help tailor specific treatments to individuals suffering from breast cancer, improving their quality of life and helping them battle back to health."

About Rna Diagnostics Inc.
Rna Diagnostics Inc. is an Ontario based molecular diagnostics company developing diagnostic tools to assist in the management of cancer chemotherapy. The company's first product, RNA Disruption Assay™ (RDA™), is a novel test that helps oncologists rapidly determine if continued chemotherapy will lead to success. RDA can determine whether a particular chemotherapy is working effectively in the patient early in treatment thereby guiding clinical decision making. For more information on Rna Diagnostics Inc., please visit www.rnadiagnostics.com.

About HTX
From Innovation through to Innovation to International Invoice, HTX supports emerging and established Ontario-based companies to develop, produce and commercialize innovative market leading advanced health technologies. For more information about the Health Technology Commercialization Program, please visit www.htx.ca. HTX is supported by the Ontario Ministry of Economic Development and Innovation, and is a member of the provincially funded Ontario Network of Excellence - a network of organizations that help entrepreneurs turn innovative ideas into jobs.

SOURCE htx.ca - the Health Technology Exchange (HTX)

For further information:

Stephanie Evans, Operations Manager
647-258-0381 x221

Organization Profile

htx.ca - the Health Technology Exchange (HTX)

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890